Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

• Status: Completed
• Trial end date: 2013-05-01

Summary

The purpose of this study is to establish the safety of orally administered PCI-32765 in combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL).

• Phase: Phase 1

Details

• Lead Sponsor: Pharmacyclics LLC.
• Treatments: Bendamustine Hydrochloride; Cyclophosphamide; Fludarabine; Rituximab